Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 608-670-1 | CAS number: 31831-53-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 18 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 441 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90-day rat study with CAPA 2043. A corrected starting point (inhalation NOAEC) of 441 mg/m3 can be calculated based on activity (*6.7/10) and breathing rate (/0.38), and for the relative extent of oral (50%) and inhalation absorption (100%).
- AF for dose response relationship:
- 1
- Justification:
- Default value
- AF for differences in duration of exposure:
- 2
- Justification:
- Default value: extrapolation from a sub-chronic study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not required: allometric factors are already accounted for in derivation of the corrected starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- Default value for workers
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: a good quality database is available
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: there are no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90 -day rat study with CAPA 2043. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 500 mg/kg bw/d is therefore calculated.
- AF for dose response relationship:
- 1
- Justification:
- Default value
- AF for differences in duration of exposure:
- 2
- Justification:
- Extrapolation from a sub-chronic study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: the starting point is derived from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- Default value for workers
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: a good quality database is available
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: there are no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
CAPA 2043 (2 -oxepanone, polymer with 1,4-butanediol) is of low acute toxicity, is not classified for skin or eye irritation or for skin sensitisation. The substance is not mutagenic based on studies in vitro. A 90 -day repeated dose oral toxicity study performed with CAPA 2043 in the rat reports a NOAEL of 500 mg/kg bw/d. A NOAEL of 800 mg/kg bw/d is determined for a developmental toxicity study performed in the rat with CAPA 2043. The NOAEL of 500 mg/kg bw/d from the 90-day study is therefore the relevant starting point for DNEL derivation.
Worker DNEL derivation
Inhalation DNELs
Systemic inhalation DNELs
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90-day rat study with CAPA 2043. A corrected starting point (inhalation NOAEC) of 441 mg/m3 can be calculated based on activity (*6.7/10) and breathing rate (/0.38), and for the relative extent of oral (50%) and inhalation absorption (100%). Individual assessment factors of 1 (for dose-response relationship), 2 (for duration of exposure), 1 (for allometric scaling), 2.5 (for other interspecies differences), 5 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 25. Application of the overall assessment factor to the corrected starting point results in a long-term systemic DNEL of 18 mg/m3. CAPA 2043 is of low acute toxicity and is not classified for acute toxicity. In the absence of any identified hazard, an acute systemic inhalation DNEL is not proposed.
Local inhalation DNELs
CAPA 2043 is not an irritant or sensitiser; therefore local effects on the repiratory tract are not predicted. Local inhalation DNELs are not proposed in the absence of any identified hazard.
Dermal DNELs
Systemic dermal DNELs
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90 -day rat study with CAPA 2043. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 500 mg/kg bw/d is calculated. Individual assessment factors of 1 (for dose-response relationship), 2 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 5 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 100. Application of the overall assessment factor to the corrected starting point results in a long-term systemic DNEL of 5 mg/kg bw/d. CAPA 2043 is of low acute toxicity and is not classified for acute toxicity. In the absence of any identified hazard, an acute systemic dermal DNEL is not proposed.
Local dermal DNELs
CAPA 2043 is not a skin irritant or sensitiser; therefore local dermal effects are not predicted. Local dermal DNELs are not proposed in the absence of any identified hazard.
Hazard for the eyes
CAPA 2043 is not classified as an eye irritant. No hazard is identified.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 217 mg/m³
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90-day rat study with CAPA 2043. A corrected starting point (inhalation NOAEC) of 217 mg/m3 can be calculated based on breathing rate (/1.15) and for the relative extent of oral (50%) and inhalation absorption (100%).
- AF for dose response relationship:
- 1
- Justification:
- Default value
- AF for differences in duration of exposure:
- 2
- Justification:
- Default value: extrapolation from a sub-chronic study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not required: allometric factors are already taken into acount in derivation of the corrected starting point
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: a good quality dataset is available
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: there are no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the oral 90-day rat study with CAPA 2043. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 500 mg/kg bw/d is therefore calculated.
- AF for dose response relationship:
- 1
- Justification:
- Default value
- AF for differences in duration of exposure:
- 2
- Justification:
- Default value: extrapolation from sub-chronic study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: the starting point is derived from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: a good quality database is available
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: there are no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 500 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
Correction of the starting point is not required as this is derived from an oral study.
- AF for dose response relationship:
- 1
- Justification:
- Default value
- AF for differences in duration of exposure:
- 2
- Justification:
- Default value: extrapolation from sub-chronic study to chronic exposure
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default value: the starting point is derived from a rat study
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 10
- Justification:
- Default value: general population
- AF for the quality of the whole database:
- 1
- Justification:
- Default value: a good quality database is available
- AF for remaining uncertainties:
- 1
- Justification:
- Default value: there are no significant remaining uncertainties
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
CAPA 2043 (2 -oxepanone, polymer with 1,4 -butanediol) is of low acute toxicity, is not classified for skin or eye irritation or for skin sensitisation. The substance is assumed not to be mutagenic based on studies in vitro. A 90 -day repeated dose oral toxicity study performed with CAPA 2043 in the rat reports a NOAEL of 500 mg/kg bw/d. A NOAEL of 800 mg/kg bw/d is determined for a developmental toxicity study performed in the rat with CAPA 2043. The NOAEL of 500 mg/kg bw/d from the 90-day study is therefore the relevant starting point for DNEL derivation.
General Population DNEL derivation
Inhalation DNELs
Systemic inhalation DNELs
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the 90-day oral rat study with CAPA 2043. A corrected starting point (inhalation NOAEC) of 217 mg/m3 can be calculated based on breathing rate (/1.15), and for the relative extent of oral (50%) and inhalation absorption (100%). Individual assessment factors of 1 (for dose-response relationship), 2 (for duration of exposure), 1 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 50. Application of the overall assessment factor to the corrected starting point results in a long-term systemic inhalation DNEL of 4 mg/m3. CAPA 2043 is of low acute toxicity and is not classified for acute toxicity. In the absence of any identified hazard, an acute systemic inhalation DNEL is not proposed.
Local inhalation DNELs
CAPA 2043 is not an irritant or sensitiser; therefore local effects on the respiratory tract are not predicted. Local inhalation DNELs are not proposed in the absence of any identified hazard.
Dermal DNELs
Systemic dermal DNELs
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the 90-day oral rat study with CAPA 2043. In the absence of data on the extent of dermal absorption, this is assumed to be equivalent to oral absorption (worst case default). A corrected dermal starting point (NOAEL) of 500 mg/kg bw/d is calculated. Individual assessment factors of 1 (for dose-response relationship), 2 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 200. Application of the overall assessment factor to the corrected starting point results in a long-term systemic dermal DNEL of 2.5 mg/kg bw/d. CAPA 2043 is of low acute toxicity and is not classified for acute toxicity. In the absence of any identified hazard, an acute systemic dermal DNEL is not proposed.
Local dermal DNELs
CAPA 2043 is not a skin irritant or sensitiser; therefore local dermal effects are not predicted. Local dermal DNELs are not proposed in the absence of any identified hazard.
Oral DNELs
The relevant starting point is the NOAEL of 500 mg/kg bw/d from the 90-day oral rat study with CAPA 2043. Correction of the starting point is not required. Individual assessment factors of 1 (for dose-response relationship), 2 (for duration of exposure), 4 (for allometric scaling), 2.5 (for other interspecies differences), 10 (for intraspecies differences), 1 (for database quality) and 1 (for remaining differences) are used, resulting in an overall assessment factor of 200. Application of the overall assessment factor to the corrected starting point results in a long-term systemic oral DNEL of 2.5 mg/kg bw/d. CAPA 2043 is of low acute toxicity and is not classified for acute toxicity. In the absence of any identified hazard, an acute systemic oral DNEL is not proposed.
Hazard for the eyes
CAPA 2043 is not classified as an eye irritant. No hazard is identified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
